high level of expression associated with poor prognosis in p-stage I adenocarcinoma of the lung

polymorphism and overexpression of Thymidylate synthase mrna is associated with non-small-cell lung cancer

thymidylate synthase and dihydropyrimidine dehydrogenase are involved in resistance to 5-fluorouracil in human lung cancer cells

head & neck, gastric, colorectal, breast, lung & pancreatic cancer were examined; findings show mRNA expression & protein level of thymidylate synthase, dihydropyrimidine dehydrogenase & orotate phosphoribosyltransferase differed according to cancer type

protein expression neither influenced the prognosis nor predicted the response to pemetrexed in Korean patients with advanced non-small cell lung cancer

Advanced lung adenocarcinoma patients with low TS expression had significantly higher control rate by pemetrexed treatment than those with TS overexpression.

Insight into the biological relevance of thymidyltate synthase (TS) as well as a basis for clinical development of TS-targeted therapy for lung cancer.

Thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase play a role in the prognosis of non-small-cell lung cancer.

upregulated expression is a marker for predicting postoperative recurrence in patients with lung adenocarcinoma

tumor expression levels of thymidylate synthetase and dihydropyrimidine dehydrogenase are predictive of response to S-1-carboplatin chemotherapy in patients with advanced non-small cell lung cancer

Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

Low thymidylate synthase expression is associated with treatment response in non-small cell lung cancer.

A positive TS expression was a powerful prognostic factor to predict a poor outcome in completely resected non-small cell lung cancer patients

High thymidylate synthase expression is associated with response to therapy in non-small-cell lung cancer.

This study showed that TS protein is highly expressed in NSCLC and that polymorphisms of TS 3'-UTR 1494del 6 bp are associated with sensitivity of lung adenocarcinoma patients to pemetrexed treatment

Low thymidylate synthase expression is significantly associated with better response rate and progression-free survival in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy.

Thymidylate synthase gene copy number is associated with response to pemetrexed treatment of lung adenocarcinoma.

High thymidylate synthase expression is associated with response to therapy in nonsquamous non-small-cell lung cancer.

High TMYS expression is associated with non-small cell lung cancer.

Low/negative TYMS expression was significantly associated with higher response rate and longer survival of advanced non-small cell lung cancer patients receiving pemtrexed-based chemotherapy. (Meta-analysis)

Data suggest that expression of TYMS can be used as biomarker of response to pemetrexed-containing chemotherapy in non-small-cell lung cancer patients; lower expression of TYMS is associated with better response. [META-ANALYSIS; REVIEW]

High is thymidylate synthetase associated with low response to chemotherapy in non-small-cell lung cancer.

TYMS gene amplification predicts outcome of patients receiving pemetrexed with advanced non-small cell lung cancer.

TYMS overexpression was detected in 61 % of non-small cell lung cancer patients and low expression in 39 %.

treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer, were evaluated.

Thymidylate Synthase Polymorphisms are associated with the Risk of lung cancer.

High expression level of TYMS is associated with neuroendocrine lung tumors.

These findings suggested that the down-regulation of AKT-mediated TS expression by salinomycin enhanced the cisplatin-induced cytotoxicity in nonsmall cell lung cancer cells.

The Thymidylate synthase (TS)-ZEB1 association was confirmed in clinical specimens from lung tumours and in a genetic mouse model of pancreatic cancer with ZEB1 deletion. Interestingly, TS itself appeared to have a regulatory role in epithelial-to-mesenchymal in cancer cells, as TS knockdown could directly reduce the EMT phenotype, the migratory ability of cells, the expression of stem-like markers, and chemoresistance.

This study demonstrates a significant correlation between low TS expression levels and long-term prognosis of patients with lung cancer.

There was significantly higher thymidylate synthase (TS) expression in non-small cell lung cancer (NSCLC) tumor tissue comparing to normal lung tissue.

the present results indicate that the EGFR mutation status and TS and ERCC1 expression can be used as the predictors of overall survival after subsequent second-line treatments for adenocarcinoma non-small-cell lung cancer

Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase expression Status in Patients with Advanced lung Adenocarcinoma Using a Radiomics Approach.

24 hr. pretreatment with dexamethasone, but not same day co-administration of dexamethasone with therapy, impairs the TS inhibition-mediated "flare" in thymidine salvage pathway activity in non-small cell lung cancer.

Polymorphism rs3819102 in thymidylate synthase gene is associated with lung cancer.

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.